Document is current
Any future updates will be listed below
-
Authors
Yu, Yingduo
Yao, Qigu
Chen, Deying
Zhang, Zhehua
Pan, Qiaoling
Yu, Jiong
Cao, Hongcui https://orcid.org/0000-0002-6604-6867
Li, Liang
Li, Lanjuan
-
Funding
Funding for this research was provided by:
National Key R&D Program of China (No. 2020YFA0113003)
High-level personnel cultivating project of Zhejiang Province (No. 2023R5243)
Fundamental Research Funds for the Central Universities (No. 2022ZFJH003)
Central Guidance Fund for Local Science and Technology Development (2024ZY01054)
- License Information
-
More Information
Article History
Received: 29 April 2024
Accepted: 29 September 2024
First Online: 8 October 2024
Declarations
:
: All experiments involving hP-MSCs were approved by The Ethics Committee of The First Affiliated Hospital of Zhejiang University School of Medicine (Title of approved project: Clinical-grade stem cell product development and transplantation for the treatment of autoimmune diseases and other clinical studies; Approval number: No. 2021–0158; Date of approval: March 08, 2021). hP-MSCs were sourced from the placentas of donors from The First Affiliated Hospital of Zhejiang University School of Medicine. Written informed consent was obtained from all individual participants included in the study. All experiments involving animals were approved by The Ethics Committee of The First Affiliated Hospital of Zhejiang University School of Medicine (Title of approved project: Clinical-grade stem cell product development and transplantation for the treatment of autoimmune diseases and other clinical studies; Approval number: No. 2020-1088; Date of approval: May 15, 2020). In addition, all the animal procedures were followed ARRIVE (Animal Re-search: Reporting of In Vivo Experiments) guidelines.
: Not applicable.
: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
